Amsterdam: From its glass tower on the edge of the Dutch capital, the European Medicines Agency is preparing for the biggest change to its work in a generation. After reaching political agreement earlier this year, the Union is rewriting the medicine rules that govern how drugs are developed, approved and kept on pharmacy shelves, replacing a legal framework that has stood for more than two decades.
The reform is sweeping by design. It sweeps away the longstanding Community Code and the regulation that created the agency itself, folding them into a single new regulation and directive. The stated aim is to modernise every stage of a medicine’s life, from early development support through authorisation to the safety monitoring that continues long after a drug reaches patients. Rare-disease and children’s medicines get particular attention, as do the shortages that have left pharmacies scrambling in recent winters.
At the centre of the bargain lies a trade over incentives. Drugmakers value the years of regulatory data protection that shield a new medicine from competition, and the reform recalibrates that reward, offering companies extra protection when they launch across all member states or address unmet needs. Public-health advocates argue the old system let firms concentrate on the richest markets while smaller countries waited; industry warns that trimming incentives could push research elsewhere. The final text tries to thread that needle.
Patients should notice more practical changes too. The package pushes electronic product information, letting the paper leaflet folded inside every box give way to digital formats that can be updated quickly and read in any language. The agency would also become a clearer single point of information, and its scientific committees are restructured to speed decisions. Environmental sustainability, long absent from pharmaceutical law, enters the rulebook for the first time.
None of it happens overnight. The adopted acts are expected to enter into force this year, followed by a transition running to 2028 during which every member state must update national law to match. That gap is where the real work sits, because a reform agreed in principle can still stumble in translation across twenty-seven legal systems. The agency, for its part, has built preparation for the changes into its own work programme for the year.
The prize is a system that gets medicines to patients faster and more evenly, with fewer shortages and less paperwork; the risk is that a long transition and complex incentives blunt the ambition before it takes hold. The agency explains the shape of the new medicine rules through its guide to the pharmaceutical reform, and the Council sets out the political bargain behind the pharma package. The next two years will decide whether the overhaul lives up to its billing.
